

Clatterbridge Cancer Centre Performance in Delivering Research Q4 2014-15 (Apr 14 - Mar 15)

Id	Research Ethics Committee Reference Number	Name of Trial	Target number of patients	Date Agreed to recruit target number of patients	Trial Status	Target met within the agreed time	Comments
45878	13/LO/1020	Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who have Received Prior Sorafenib	5	31/01/2017	Open	N/A	Trial still open and actively recruiting
45879	14/NW/0020	NCRN 2630 Bayer 16507 A three arm randomized,1 open-label Phase II study of radium-223 dichloride 50 kBq/kg versus 80 kBq/kg, and versus 50 kBq/kg in an extended dosing schedule in subjects with castration-resistant prostate cancer metastatic to the bone	6	30/09/2023	Open	N/A	Trial still open and actively recruiting
45880	13/LO/1581	NCRN - 2643 DNIB0600A in patients with Platinum-Resistant Ovarian Cancer	4	01/01/2016	Open	N/A	Trial still open and actively recruiting
45881	14/LO/0135	controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-na?ve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)	6	30/07/2021	Open	N/A	Trial still open and actively recruiting
45882	13/SC/0478	NCRN 567 COLUMBUS - A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with vemurafenib in patients with unresectable or metastatic BRAF V600 mutant melanoma	3	21/08/2017	Open	N/A	Trial still open and actively recruiting
45883	14/LO/0022	Renal Cell WO29074 NCRN 2511 A PHASE II, RANDOMIZED STUDY OF MPDL3280A ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA	4	07/01/2017	Suspended	N/A	
45884	13/LO/1050	Carcinoma)A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma	6	01/06/2016	Open	N/A	Trial still open and actively recruiting
45885	14/SW/0091	NCRN - 2974 VESTA: NSCLC M11089 A Phase 3 Veliparib plus Chemotherapy Study in Adv/Met squamous NSCLC	8	31/03/2016	Open	N/A	Trial still open and actively recruiting
45886	14/SC/0199	Nivolumab vs therapy of investigator?s choice in recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck (SCCHN)	4	31/12/2015	Open	N/A	Trial still open and actively recruiting

45887	14/LO/1042	GO29293 - MPDL3280A in metastatic bladder cancer	5	01/05/2018	Open	N/A	Trial still open and actively recruiting
45888	14/NW/1036	of S-588410 as maintenance monotherapy after first-line platinum-containing chemotherapy in patients with advanced and/or metastatic bladder cancer	4	30/09/2017	Open	N/A	Trial still open and actively recruiting
45889	13/EM/0230	NCRN636 - VS-6063 in mesothelioma - A phase II randomised, double blind, placebo-controlled, multicentre study of VS-6063 in subjects with malignant pleural mesothelioma	8	31/12/2016	Open	N/A	Trial still open and actively recruiting
45890	14/LO/1052	Safety and Efficacy of TAK-385, an Oral GnRH Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)	10	14/09/2015	Open	N/A	Trial still open and actively recruiting
45891	14/NW/0350	A Randomized Phase IIB Open Label Study of Nivolumab or Nivolumab in Combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM) (CheckMate 143: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 143)	3	31/01/2018	Open	N/A	Trial still open and actively recruiting
45892	14/NE/1079	Efficacy of two different dose levels of orvepitant (10 and 30mg) compared with placebo on EGFRi- induced intense pruritus in oncology subjects	5	24/02/2015	Open	N/A	Trial still open and actively recruiting
45893	14/LO/1151	in Combination with Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone	15	30/08/2015	Open	N/A	Trial still open and actively recruiting
45894	14/SC/1167	CENTER, TWO-PART STUDY OF PATRITUMAB (U3-1287) IN COMBINATION WITH ERLOTINIB IN EGFR WILD-TYPE SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON AT LEAST ONE PRIOR SYSTEMIC THERAPY U31287-A-U301	6	03/08/2015	Open	N/A	Trial still open and actively recruiting
45895	14/LO/1672	Polo Pancreatic 217674	2	22/11/2017	Open	N/A	Trial still open and actively recruiting
45896	14/NW/1258	NCRN - 3041:ODM-201 IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER	6	30/06/2020	Open	N/A	Trial still open and actively recruiting
45897	14/WM/1055	NCRN - 3246: Masitinib/Placebo + FOLFIRI in Metastatic Colorectal Cancer	6	01/09/2015	Open	N/A	Trial still open and actively recruiting
45898	14/EM/0089	A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients.	2	31/10/2015	Open	N/A	Trial still open and actively recruiting

45899	14/LO/1385	REASURE (Radium-223: Evaluation of Activity and SURrogate REsponse)	6	04/05/2017	Open	N/A	Trial still open and actively recruiting
45900	14/LO/1490	A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA-4 Monoclonal Antibody	6	30/04/2019	Open	N/A	Trial still open and actively recruiting
45901	14/LO/1739	NCRN - 3036 PRESIDE Continuing enzalutamide in chemo-naive CRPC	10	01/01/2018	Open	N/A	Trial still open and actively recruiting
45902	14/LO/1788	A Phase III open-label multicenter randomised study to investigate the efficacy and safety of MPDL3280A (Anti-PD-L1 antibody) compared to chemotherapy in patients with locally advanced or metastatic bladder cancer after the failure with platinum-containing chemotherapy	6	18/12/2017	Open	N/A	Trial still open and actively recruiting
45903	14/SC/1014	Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study)	5	26/01/2016	Open	N/A	Trial still open and actively recruiting